Toxoplasma gondii, a eukaryotic brain parasite that infects one in three people worldwide, was engineered to deliver therapeutics to neurons in the mouse brain. This technology opens the door to deliver multiple large proteins that have been undeliverable with previous approaches. Further development, such as vector attenuation, will be necessary for many applications.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood–brain barrier. Nat. Rev. Drug Discov. 20, 362–383 (2021). A review of current approaches for delivery of therapeutics, particularly those that are protein-based, across the BBB.
Lodoen, M. B., Gerke, C. & Boothroyd, J. C. A highly sensitive FRET-based approach reveals secretion of the actin-binding protein toxofilin during Toxoplasma gondii infection. Cell. Microbiol. 12, 55–66 (2010). The first demonstration of toxofilin fusion driving secretion from the rhoptries.
Notin, P., Rollins, N., Gal, Y., Sander, C. & Marks, D. Machine learning for functional protein design. Nat. Biotechnol. 42, 216–228 (2024). A review of recent machine-learning techniques for protein design and engineering that will unlock new types of tools and therapeutics, requiring compatible delivery approaches.
Oladejo, M., Paterson, Y. & Wood, L. M. Clinical experience and recent advances in the development of Listeria-based tumor immunotherapies. Front. Immunol. 12, 642316 (2021). A paper describing the development of current Listeria-based immunotherapies and the gradual improvement of their safety profile by strain attenuation.
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Sig. Transduct. Target. Ther. 6, 53 (2021). A review of the history and development of viral vectors for gene therapy and their attenuation for improved safety and clinical application.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Bracha, S. et al. Engineering Toxoplasma gondii secretion systems for intracellular delivery of multiple large therapeutic proteins to neurons. Nat. Microbiol. https://doi.org/10.1038/s41564-024-01750-6 (2024).
Rights and permissions
About this article
Cite this article
Harnessing a brain parasite as a tool for delivery of therapeutics to the brain. Nat Microbiol 9, 1914–1915 (2024). https://doi.org/10.1038/s41564-024-01772-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41564-024-01772-0
